Posters & Presentations

Gateway Analytical is well-represented at top technical conferences around the globe, where our scientists often present on our unique capabilities and findings. Our posters and slides are below.

Bringing the latest conference to your desktop.

RDD 2015 Workshop: Assessing Aggregate Performance and the Presence of Foreign Particulate in OINDPs

May 19, 2015 Establishing bioavailability and proving bioequivalence of inhaled combination therapies can be difficult without addressing two major concerns: accurate and precise particle size distribution data of the individual active pharmaceutical ingredient and source determination of the any existing foreign particulate matter. Raman spectroscopy and Raman chemical imaging have…

Gateway Analytical to Present at 2012 MAAFS Meeting: The Introduction of Hyperspectral Imaging as an Additional Method of Examination for Tapes

Authors & Contributors Cara Plese May 10, 2012 The Mid-Atlantic Association of Forensic Scientists (MAAFS) annual meeting is being held later this month from May 14th through the 18th.  MAAFS is one of several regional/state forensic science associations in the United States.  Regional meetings are great for scientists to attend because they usually require less travel than…

2014 ASSA International IWPCPS-16 Workshops: Spatially-Resolved Raman Imaging for Ingredient-Specific Characterization of Combination Dry Powder Inhalers

June 17, 2014 Since the approval of Dry Powder Inhalers containing Fluticasone Propionate and Salmeterol Xinafoate in 1999, combination inhaled therapies have dominated the COPD market. However, due to the lack of specific guidance of the Office of Generic Drugs  as to the abbreviated new drug application submission, there was…

DDL 2014: Chemically-specific Characterization of Particulate in Inhalable Drug Products using Raman and Laser-induced Breakdown Spectroscopy

December 11, 2014 The impact of foreign particulate and agglomerates on dissolution profile and permeability of the inhalable drug particles within the sites of action (i.e. patient’s lungs) is critical. In this study, Raman Chemical Imaging (RCI) and Raman/ Laser-induced breakdown spectroscopy (LIBS) were used to investigate the Active Pharmaceutical…

RDD 2013: Polymorph Identification of Drug Particles in Orally Inhaled and Nasal Drug Products

June 04, 2013 Authored by Oksana Olkhovyk, Ph.D., at Gateway Analytical , this poster presents new qualitative and semi-qualitative methods for the examination of size and polymorph drug particle identification in finished products. Specifically, its benefits for BA/BE testing is described using the model of fluticasone-containing nasal spray suspension formulation.…

2014 IACP Conference: The Evolution of Gunshot Residue Analysis

Authors & Contributors David Exline Emily Landsperger Cara Plese November 19, 2014 Gunshot residue analysis is a common request in forensic laboratories with cases that question whether or not anindividual fired a firearm. When a firearm is fired, several types of residues are expelled from the openings on the firearm. Primer residues, specifically,…

Early-Phase Development

Comprehensive packages designed to navigate clinical & regulatory complexities of parenteral product-package and container-closure development, from concept to market readiness.

Container Closure
Integrity Testing

Quantitative, non-destructive, deterministic leak detection technologies for products stored in vials, syringes, cartridges, flexible containers, and bottles.

Particulate
Analysis

Multi-analytical methods to count, size, and characterize visible and subvisible particulate matter in pharmaceuticals, disposable containers, single-use systems, raw materials, and medical devices.

Medical Device
Analysis

Rigorous studies focused on enumerating particulate matter and identifying potential chemical compounds that could migrate from medical devices into the environment or directly impact patient health.

Extractables
& Leachables

Studies aimed at identifying potentially harmful compounds in manufacturing components and final containers to ensure the safety and efficacy of pharmaceutical products.

Empowering Your Journey Toward Enhanced Patient Care

Covering every stage of the drug development journey with our state-of-the-art, FDA-inspected, cGMP-compliant facilities designed to minimize bottlenecks and maximize success.